Stocks

Why Canopy Growth Corp stock is skyrocketing today

By Wealth Awesome Newsroom -
Stocks & ETFs:WEED.TO
Photos provided by Pexels

Canopy Growth Corp is making headlines with a notable surge in its stock price, driven by impressive growth in its medical marijuana sales.

In the latest trading session, Canopy Growth Corp (WEED.TO) saw its stock price soar by 7.58%, closing at CA$1.42. This increase follows strong performance in its medical marijuana segment, which has been a bright spot for the company amid mixed results in other areas.

Investor takeaway: While Canopy Growth's medical marijuana sales are showing promising growth, investors should remain cautious about the overall health of the company's other business segments.

Advertisement

Qtrade Direct Investing

Get up to $2,000 cash back

Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.

Canopy Growth Corp

WEED.TO

Full stock page โ†’

WEED.TO

Canopy Growth Corp

Source:WealthAwesomeWealthAwesome
โ†“ $0.28 (-17.28%)
120 day period
$1.20$1.54$1.89Jan 19Apr 17Jul 14

Market cap

$614.33M

52W high

$3.28

52W low

$1.18

1W change

-1.47%

Beta

2.42

Analyst Price Targets

Based on analyst covering WEED

๐Ÿ“ˆ

Wall Street analysts forecast WEED stock price to rise 50.7% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$2.02

+50.7% Upside

Current Price

C$1.34

Last close

Analyst ratings and price targets are updated periodically. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on WEED's historical volatility

HistoricalForecast68%95%
C$0.69C$0.94C$1.19C$1.44C$1.69C$1.95TodayMar 3May 8Jul 14Aug 26Oct 9Nov 21

30-Day Vol

38.4%

Annualized

90-Day Vol

64.4%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$1.12

Expected price

HorizonExpected68% Range (1ฯƒ)
30 trading daysC$1.26C$1.11 โ€“ C$1.44
60 trading daysC$1.19C$0.99 โ€“ C$1.43
90 trading daysC$1.12C$0.89 โ€“ C$1.41

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯƒ, 95% band = ยฑ2ฯƒ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Canopy Growth's Medical Marijuana Sales Soar by 27%

The company's medical marijuana segment has outperformed expectations, significantly contributing to its recent stock price increase.

Bull case

The 27% increase in medical marijuana revenue for the fourth quarter shows strong demand and hints at a possible turnaround for Canopy Growth. The acquisition of MTL Cannabis could further enhance its market position, making it an attractive option for investors seeking growth in the cannabis sector.

Bear case

Despite the positive news, Canopy Growth's recreational marijuana segment struggled, with only a 1% revenue increase in the fourth quarter. Additionally, the company's ongoing negative earnings and declining gross margins raise concerns about its long-term viability.

Strong Growth in Medical Marijuana Sales

Canopy Growth's recent report highlighted a remarkable 27% increase in medical marijuana revenues for the fourth quarter of fiscal 2026. This growth is a positive indicator for the company, especially as it continues to strengthen its position in the Canadian medical marijuana market through strategic acquisitions like MTL Cannabis. Investors may find this segment a beacon of hope amidst the company's broader challenges.

Mixed Results in Other Segments

While the medical marijuana division is thriving, Canopy Growth's recreational cannabis business only saw a 1% revenue increase in the fourth quarter. This raises concerns about the sustainability of growth in this area. Additionally, the company's international cannabis sales experienced a year-over-year decline despite a quarterly increase, indicating potential supply chain issues that could affect future performance.

What Lies Ahead for Canopy Growth

Investors should approach Canopy Growth with caution. The recent stock surge is encouraging, but the company has not reported positive earnings since going public over a decade ago. With ongoing challenges in several business segments and a recapitalized balance sheet, it may take more than just one successful division to restore investor confidence in Canopy Growth. For those interested in the cannabis sector, it might be wise to monitor developments closely before making any investment decisions.

Advertisement

Sponsored links

Advertisement